u/yannick_barros

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

Hair shedding after significant weight loss is a telogen effect that follows the rate of loss. It is not specific to these compounds and it resolves.

Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

Agreed that thin testing here says something about the members, not about the material.

potency testing on the finished preparation is the thing to ask for

Do you have the trace, or only the summary?

Is that the 48-week figure or an earlier readout?

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

the shortage list is the whole legal hinge and people skip it

Panicked over a first-day sensor reading and rebuilt my week around it. It was the sensor.

half-life is why these are weekly and not daily

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material.

Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.

First result I ever posted here got asked for the batch number and the claim.

Agreed — and two services on one batch is the strongest thing any of us can produce individually.

Merged with the other thread on the same batch so the results sit together.

peptidemeter_pat is right that the band matters more than the peak. Consistency across lots is the finding.

Yes — the person managing your diabetes is the one to talk to, and this board is explicit about that.

What does time in range look like, not just the average?

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

inter-lab variance runs a point or two, plan your outrage accordingly

Kept a log specifically because there is so little published. It is one person and it is not data.

I would not post that as a finding. It is a single result and the template asks you to say so.

I would not post that as a finding. It is a single result and the template asks you to say so.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Yes. Two services on the same batch is the strongest thing an individual member can produce, and it is not expensive.

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.

Stocked lines and made-to-order lines have different lead times and different storage histories. Both are ordinary; the difference is worth confirming before you commit.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

Agreed. Slowing down at meals did more for my nausea than everything I bought to fix it, which was embarrassing to discover.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Stocked line or made to order — did they say?

Small fix — three receptors, not two.

nadia_norgaard is right about the escalation being the variable. It explains most of the difficult reports here.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

Yes. Naming conventions in this corner are loose enough that the same word covers several different molecules.

The template is vendor, compound, batch, service, claim, result, and who paid.

Disagreeing with this line: that gap is ordinary variance, not a contradiction between the lab and the certificate.